INTRODUCTION:
Madhumeha, often correlated with Diabetes Mellitus stands as a global problem. Diabetes Mellitus is the most common of the serious metabolic diseases. When a patient presents sign and symptoms attributable to an osmotic diuresis and is found to have hyperglycemia, essentially all the physicians agree that Diabetes is present. It was well known to the ancient Indian Physicians who described not only the sweet taste of urine as one of the major symptoms but also the relationship of the disease with obesity and consequences of bio-chemical abnormalities in the body creating dislipidaemia in the glucose metabolism.
An elaborate description of its clinical features and effective management are seen in classical texts. A number of herbal preparations and plant extracts have been used with varying degree of success in the management of NIDDM. In the present study on herbal preparation viz.
Nishamalaki was taken under trial and its effects on clinical features, blood and urine sugar levels was assessed.
MATERIAL AND METHODS:
1. Selection of cases:-Clinical trail of the drug was carried out in the CRI(Ay.). hospital at Jaipur.
Patients belonging to the near by areas of Jaipur were selected to ensure regular follow up.
• Patients were randomly divided in two groups. Group A and B the groups contained 25 patients having at least two follow up. All the patients were between age group of 30 to 70 yrs. Having diagnosed as NIDDM.
• Patients of group -A were administered a placebo (Barley Powder) in a dose of one gram thrice daily for six weeks along with diet control and they were followed every Fortnightly.
• Patients of group B were …. Every fortnightly.
• Patients diagnosed as IDDM and individuals having systematic complications were considered unfit for the studies.
H. Parameters for Assessment:
• Clinical parameters: Certain classical sign and symptoms based on the protocol cleared by the respective ethical committee of CCRAS were taken up for study e.g. Prabhutamutrata (polyuria), avilamutrata (Turbid urine), Kshudhadhikya (Poly phagia) Trisha (Polydypsia) and Sthaulya (obesity). Symptoms were graded as 'O' (Nil), '4' (Mild), '7' (Moderate and '10' as severe 
RESULTS AND OBSERVATION TABLE NO.1. INCIDENCE OF AGE & SEX
*n= 25 Table shows that most of the patient in both the groups were in the age group of 41-50yrs. 
S.No. Age group (Yrs.)
Group Male Female 1.
2.
3.
4.

31-40
41-50
51-60
61-70
*n= The table shows that Dvandaja Prakriti was predominant in both groups. 
DISCUSSION:
• The indigenous compound drug Nishamalaki selected for clinical trial is a combination of Haridra (Curcuma longa) and amalaki (Emblica officinalis), also advocated by Vagbhata as a drug of choice for the treatment of prameha. Shamaka properties. Haridra is well known as a blood purifier while the Amalaki has a potent Rasayana effect.
• Group B, in general showed better response to the treatment considering symatology and decrease in the level of blood and urine sugar. This indicates the efficacy of drug as hypoglycemic agent.
• Patients with NIDDM have two physiologic defects, abnormal insulin secretion and resistance to insulin action in target tissues.
• Insulin resistance may be due to any one of three general causes; an abnormal insulin molecule, an excessive amount of circulting anti bodies and target tissue defects.
• It may be possible that this medicine may have some role against circulating antagonists and on the target tissue defects. Both the medicines included in the compound have Tridosa shamaka AND Rasayana property. They are acting at the level of Rasa, Agni and Srotas, thus they may exert a positive response on the whole system
• Response of the treatment was found better among the individuals having Kaphja content in their body constitution, favours the better prognosis of Kapahaja prameha as described in the classics.
• No untoward effect was observed during the period of therapy.
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CONCLUSION:-
The drug Nishamalaki seems to be a simple, safe and cost effective remedy for the treatment of Diabetes mellitus. It may not be so useful in the individuals having fasting blood sugar levels above 200 mg%. In such condition oral hypoglycemic agent may be added. Having high safety profile this drug may also be used as adjuvant along with the modern oral hypoglycemic agents.
